BDRX
Biodexa Pharmaceuticals Plc

12,145
Mkt Cap
$2.71M
Volume
8,510.00
52W High
$92.00
52W Low
$3.58
PE Ratio
-0.07
BDRX Fundamentals
Price
$4.38
Prev Close
$3.93
Open
$3.93
50D MA
$6.53
Beta
1.25
Avg. Volume
327,672.74
EPS (Annual)
-$148.23
P/B
10.30
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago
News Placeholder
More News
News Placeholder
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks·6mo ago
News Placeholder
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
Stocktwits·10mo ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
News Placeholder
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (Biodexa or the Company) (NASDAQ: BDRX). Investors...
Business Wire·1y ago
News Placeholder
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm BDRX INVESTOR ALERT: Bronstein...
PR Newswire·1y ago
News Placeholder
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biodexa Pharmaceuticals Plc (Biodexa or the Company) (NASDAQ: BDRX). Investors...
Business Wire·1y ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRX SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...
PR Newswire·1y ago
News Placeholder
Why Is Brain Cancer-Focused Biodexa Pharmaceuticals Stock Trading Lower On Thursday?
Biodexa Pharmaceuticals reports updates from the MAGIC-1 study on MTX110 for recurrent glioblastoma. MTX110 has also demonstrated potential in treating diffuse midline glioma, a rare brain cancer...
Benzinga·1y ago

Latest BDRX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.